Literature DB >> 17090705

An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

C E Groer1, K Tidgewell, R A Moyer, W W Harding, R B Rothman, T E Prisinzano, L M Bohn.   

Abstract

G protein-coupled receptor desensitization and trafficking are important regulators of opioid receptor signaling that can dictate overall drug responsiveness in vivo. Furthermore, different mu-opioid receptor (muOR) ligands can lead to varying degrees of receptor regulation, presumably because of distinct structural conformations conferred by agonist binding. For example, morphine binding produces a muOR with low affinity for beta-arrestin proteins and limited receptor internalization, whereas enkephalin analogs promote robust trafficking of both beta-arrestins and the receptors. Here, we evaluate muOR trafficking in response to activation by a novel mu-selective agonist derived from the naturally occurring plant product, salvinorin A. It is interesting that this compound, termed herkinorin, does not promote the recruitment of beta-arrestin-2 to the muOR and does not lead to receptor internalization. Moreover, whereas G protein-coupled receptor kinase overexpression can promote morphine-induced beta-arrestin interactions and muOR internalization, such manipulations do not promote herkinorin-induced trafficking. Studies in mice have shown that beta-arrestin-2 plays an important role in the development of morphine-induced tolerance, constipation, and respiratory depression. Therefore, drugs that can activate the receptor without recruiting the arrestins may be a promising step in the development of opiate analgesics that distinguish between agonist activity and receptor regulation and may ultimately lead to therapeutics designed to provide pain relief without the adverse side effects normally associated with the opiate narcotics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090705      PMCID: PMC3926195          DOI: 10.1124/mol.106.028258

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  41 in total

Review 1.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 2.  A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists.

Authors:  I R Bruns; S Chhum; A T Dinh; H Doerr; N R Dunn; Y T Ly; C L Mitman; H D Rickards; C Sol; E W Wan; R B Raffa
Journal:  J Clin Pharm Ther       Date:  2006-04       Impact factor: 2.512

3.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

6.  Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.

Authors:  N T Burford; L M Tolbert; W Sadee
Journal:  Eur J Pharmacol       Date:  1998-01-19       Impact factor: 4.432

7.  Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits.

Authors:  M M Belcheva; Z Vogel; E Ignatova; T Avidor-Reiss; R Zippel; R Levy; E C Young; J Barg; C J Coscia
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

8.  Morphine activates opioid receptors without causing their rapid internalization.

Authors:  D E Keith; S R Murray; P A Zaki; P C Chu; D V Lissin; L Kang; C J Evans; M von Zastrow
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

9.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

10.  Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.

Authors:  Diane Gesty-Palmer; Minyong Chen; Eric Reiter; Seungkirl Ahn; Christopher D Nelson; Shuntai Wang; Allen E Eckhardt; Conrad L Cowan; Robert F Spurney; Louis M Luttrell; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

View more
  105 in total

Review 1.  Serotonin receptor signaling and regulation via β-arrestins.

Authors:  Laura M Bohn; Cullen L Schmid
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-07       Impact factor: 8.250

2.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

Review 5.  Functional selectivity of GPCR signaling in animals.

Authors:  Lei Zhou; Laura M Bohn
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

6.  Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Authors:  Marta Busnelli; Aude Saulière; Maurice Manning; Michel Bouvier; Celine Galés; Bice Chini
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

7.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

8.  Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.

Authors:  Elliott J Sally; Heng Xu; Christina M Dersch; Ling-Wei Hsin; Li-Te Chang; Thomas E Prisinzano; Denise S Simpson; Denise Giuvelis; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Edward J Bilsky; Richard B Rothman
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

9.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

10.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.